United States Drug Patent 5,089,509: Claim Scope, Tazarotene Coverage, Expiration and Patent Landscape

U.S. Patent No. 5,089,509 covers a class of pyridyl-ethynyl chroman and thiochroman compounds, pharmaceutical compositions containing them, and their use in treating psoriasis. Its most commercially important compound is ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate, commonly known as tazarotene. The patent issued on January 21, 1992, and its original 17-year term expired on January 21, 2009, absent an applicable extension. It no longer blocks generic tazarotene entry in the United States.

The patent remains commercially important as the foundational U.S. patent for tazarotene, but it has no current exclusionary value. Current competition is governed by FDA approval status, formulation patents, product-specific regulatory requirements, and later patents rather than by U.S. Patent No. 5,089,509.

What drug does U.S. Patent 5,089,509 protect?

The patent principally covers tazarotene and structurally related retinoid compounds.

Patent claim or compound	Chemical subject	Commercial relevance
Claim 4	Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate	Tazarotene
Claim 5	6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid	Tazarotenic acid
Claim 11	6-(2-(4,4,7-trimethylthiochroman-6-yl)ethynyl)nicotinic acid	Related sulfur analog
Claim 14	6-(2-(4,4-dimethylchroman-6-yl)ethynyl)nicotinic acid	Oxygen analog
Claim 15	Ethyl 6-(2-(4,4-dimethylchroman-6-yl)ethynyl)nicotinate	Oxygen analog ester
Claims 18-19	Compositions and psoriasis treatment methods	Product and method-of-use coverage

Tazarotene is a topical retinoid prodrug. It is converted in vivo to tazarotenic acid, the pharmacologically active metabolite. The patent claims both the ethyl ester and the corresponding carboxylic acid, together with numerous ester, amide, alcohol, aldehyde, ketone, acetal and ketal derivatives [1].

What chemical structures fall within the patent claims?

The patent uses several broad generic formulas. Their scope is controlled by the combination of the central ethynyl-pyridyl structure and the permitted substituents.

Core structural requirements

The claims generally require:

A pyridyl ring, designated A.
An ethynyl linker attached to the pyridyl ring.
A chroman or thiochroman ring system.
A methyl-substituted ring system.
A variable heteroatom, X, that is sulfur or oxygen.
A variable substituent, R, that is hydrogen or lower alkyl.
A side-chain position, n, ranging from zero to two in the broadest claims.
A pyridyl substituent, B, that may be a carboxylic acid, ester, amide, hydroxymethyl, aldehyde, ketone or related protected derivative.

The chemical relationship can be summarized as:

substituted chroman/thiochroman - ethynyl - pyridyl derivative

The broadest independent compound claim is claim 1. It covers both sulfur and oxygen analogs and permits a wide range of functional groups at B. Claim 10 separately covers a lower-alkyl-substituted thiochroman series. Claim 12 covers the oxygen-containing chroman series.

What does claim 1 cover?

Claim 1 is a broad Markush claim. It covers compounds with:

X equal to sulfur or oxygen;
R equal to hydrogen or lower alkyl;
R2 equal to methyl;
A equal to pyridyl;
n equal to zero, one or two; and
B selected from multiple carboxylic-acid, ester, amide, alcohol, aldehyde, ketone and protected derivative options.

The claim does not cover every retinoid or every pyridine compound. Its scope is limited by the required chroman/thiochroman-ethynyl-pyridyl architecture and by the specified substitution pattern.

The B group is unusually broad. For example, the claim reaches:

The free carboxylic acid.
Pharmaceutically acceptable salts.
Lower alkyl esters.
Larger aliphatic and cyclic esters.
Phenyl and lower alkylphenyl esters.
Mono- and disubstituted amides.
Hydroxymethyl derivatives.
Ether and ester derivatives of hydroxymethyl groups.
Aldehydes and protected aldehydes.
Ketones and protected ketones.

This structure creates substantial genus coverage, although enforceability for a particular compound would depend on claim construction, written-description support, enablement and prior-art analysis.

How do the dependent claims narrow the scope?

The dependent claims identify the most commercially relevant subgroups.

Claims 2 and 3: sulfur compounds and nicotinic acid derivatives

Claim 2 narrows claim 1 to:

X equal to sulfur;
R equal to hydrogen; and
n equal to zero or one.

Claim 3 narrows the B group to:

Carboxylic acid;
Pharmaceutically acceptable salts;
Lower alkyl esters; or
Mono- or di-lower-alkyl amides.

This subgroup contains tazarotene-related sulfur compounds.

Claims 4 and 5: tazarotene and tazarotenic acid

Claim 4 specifically claims ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate. This is tazarotene.

Claim 5 claims 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid and its pharmaceutically acceptable salts. This is tazarotenic acid and its salts.

These claims are structurally narrow and commercially significant because they identify the active pharmaceutical ingredient and its principal active metabolite.

Claims 6-9: alcohol and aldehyde derivatives

Claims 6 and 7 cover hydroxymethyl derivatives, including 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)-3-pyridylmethanol.

Claims 8 and 9 cover aldehydes, including 2-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)-5-pyridinecarboxaldehyde.

These claims expand the patent beyond the carboxylic-acid and ester series and may have been directed to intermediates, analogs or alternative pharmacological candidates.

Claims 10 and 11: trimethyl sulfur analogs

Claim 10 covers a related thiochroman series in which R is lower alkyl. Claim 11 identifies the 4,4,7-trimethylthiochroman derivative.

This subgroup is chemically distinct from tazarotene because of the additional ring methyl substituent.

Claims 12-17: oxygen analogs

Claims 12-17 cover chroman compounds in which the ring heteroatom is oxygen rather than sulfur. Claims 14 and 15 specifically identify the acid and ethyl ester forms of the dimethylchroman analog.

The oxygen analogs fall within the broader genus of claim 1 but are separately claimed to provide direct protection for that series.

What pharmaceutical compositions and methods are protected?

Claim 18: composition coverage

Claim 18 covers a pharmaceutical composition containing:

A pharmaceutically acceptable excipient; and
A compound within the defined chroman, thiochroman and pyridyl-ethynyl genus.

The claim is not limited to a specific dosage form, concentration, vehicle or route of administration. On its face, it can reach topical, oral or other pharmaceutical compositions if the composition contains a covered compound and a pharmaceutically acceptable excipient.

The claim does not expressly require a gel, cream, foam, lotion, ointment or solution. Those dosage-form limitations would generally come from the product definition, later patents, regulatory labeling or claim construction rather than from claim 18 itself.

Claim 19: psoriasis treatment

Claim 19 covers treating psoriasis in a mammal by administering a therapeutically effective amount of a covered compound, alone or with a pharmaceutically acceptable excipient.

The method claim is broader than a product claim in some respects because it does not require a specific formulation. It is limited by:

The psoriasis indication.
Administration to a mammal.
A covered compound.
A therapeutically effective amount.

Because the claim expired in 2009, it does not currently create a U.S. method-of-use barrier to approved generic tazarotene products.

When did U.S. Patent 5,089,509 expire?

U.S. Patent No. 5,089,509 issued on January 21, 1992. Under the pre-June 8, 1995 patent-term regime, the patent generally received 17 years from grant rather than 20 years from the earliest effective filing date.

Event	Date or status
Patent issued	January 21, 1992
Statutory term	17 years from issue
Expected expiration	January 21, 2009
Current status	Expired
Current U.S. blocking effect	None

The patent predates the Uruguay Round Agreements Act transition rules that established the modern 20-year-from-filing term for most later U.S. applications. No current U.S. exclusivity should be attributed to Patent No. 5,089,509 [1,2].

What is the Orange Book status of tazarotene?

Tazarotene products were approved by the FDA for topical dermatologic use, including psoriasis and acne indications. The principal branded product was marketed by Allergan under names including Tazorac and Avage, depending on dosage form and indication.

The FDA Orange Book historically listed U.S. patents associated with approved tazarotene products. Patent No. 5,089,509 was an important foundational compound and use patent for the product family. Its expiration removed the principal early patent barrier to abbreviated new drug application entry [3].

The relevant regulatory distinction is:

Patent expiry eliminates patent-based blocking rights.
FDA approval requirements remain.
Generic applicants must still establish pharmaceutical equivalence, bioequivalence where applicable, manufacturing compliance and labeling conformity.
Later formulation or delivery patents may have created separate, time-limited barriers for particular products.

Tazarotene is a small-molecule topical drug, not a biologic. Biosimilar regulation under the Public Health Service Act is therefore not applicable. Competition proceeds through the generic drug pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act, subject to product-specific FDA requirements [4].

Were Paragraph IV challenges relevant to tazarotene?

Paragraph IV litigation was commercially relevant once generic applicants sought approval for tazarotene products while patents remained listed in the Orange Book. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

For Patent No. 5,089,509, the practical significance of any Paragraph IV challenge ended with patent expiration. A generic applicant can no longer be blocked by this patent, and a new Paragraph IV certification against an expired patent would not create a meaningful remaining patent term.

The principal historical litigation risks would have involved:

Whether the generic contained the same active ingredient as tazarotene.
Whether the proposed product infringed a listed formulation or method patent.
Whether a listed patent was properly tied to the approved drug.
Whether the patent claims were valid over earlier retinoid, chroman or pyridine chemistry.
Whether the generic label carved out a patented indication.

What later patents could matter after Patent 5,089,509?

Patent No. 5,089,509 was a foundational compound patent, not a complete patent estate for every later tazarotene product. Product-specific risk could have shifted to later patents covering:

Formulations

Later patents may cover:

Topical gels.
Creams and emulsions.
Foams.
Vehicle systems.
Solubilization techniques.
Particle-size control.
Stability improvements.
Reduced-irritation formulations.
Specific concentrations such as 0.05% or 0.1%.

A generic product that uses a different vehicle may avoid a formulation patent even if it contains the same tazarotene active ingredient.

Method-of-use patents

Later patents may cover:

Acne treatment.
Psoriasis treatment.
Specific patient populations.
Combination treatment with corticosteroids or antimicrobials.
Application frequency.
Reduced irritation or improved tolerability.
Particular body sites or disease severity.

A generic applicant can sometimes rely on a section viii label carve-out for a patented use, provided the remaining label does not actively encourage the patented use.

Delivery systems

Separate patents may address:

Aerosol foam delivery.
Metered-dose topical systems.
Hydroalcoholic vehicles.
Emulsion systems.
Controlled release.
Enhanced skin penetration.

These patents do not necessarily extend protection for the tazarotene molecule itself.

How strong is the patent estate for tazarotene?

The estate was strong during the compound patent term because claim 4 directly covered tazarotene and claim 5 covered its active acid metabolite. Direct compound claims are generally more valuable than claims limited to a particular formulation or use because they can reach multiple dosage forms and indications.

Its current strength is zero as a U.S. exclusionary right because the patent expired.

Estate component	Historical strength	Current U.S. status
Tazarotene compound claim	High	Expired
Tazarotenic acid claim	High	Expired
Broad analog genus	Moderate to high, depending on validity and construction	Expired
Pharmaceutical composition claim	Moderate	Expired
Psoriasis method claim	Moderate	Expired
Later formulation patents	Product-specific	Must be reviewed individually
Manufacturing patents	Process-specific	Must be reviewed individually

The broad genus claims could have faced prior-art and enablement challenges because they encompass a large number of derivatives. The directly recited tazarotene claim was narrower and more commercially defensible, assuming validity and infringement.

Which companies challenged or competed with the patent estate?

The relevant competitive field includes:

Allergan and its successor commercial organizations, as the branded-product sponsor.
Generic manufacturers seeking approval for tazarotene cream, gel, foam or related topical products.
Dermatology companies marketing competing topical retinoids.
Manufacturers of adapalene, tretinoin and other retinoid products.

The competitive products are not necessarily chemically identical. Adapalene and tretinoin have different structures and are not covered by Patent No. 5,089,509. Their patents and regulatory histories are separate.

Public FDA records identify approved tazarotene products and abbreviated applications. The patent itself does not establish a continuing license, settlement or commercial agreement with any generic manufacturer. No current licensing restriction should be inferred from the expired patent.

How does tazarotene compare with other topical retinoids?

Product	Active ingredient	Relationship to Patent 5,089,509	Competition
Tazorac, Avage	Tazarotene	Directly covered by claims 4 and related claims	Generic tazarotene
Tretinoin products	Tretinoin	Not covered	Separate retinoid estate
Adapalene products	Adapalene	Not covered	Separate compound and formulation estate
Trifarotene products	Trifarotene	Not covered	Later-generation retinoid estate
Combination products	Tazarotene plus another active	Tazarotene component may be covered historically; combination claims require separate analysis	Formulation and combination competition

Tazarotene is distinguished by its prodrug design and conversion to tazarotenic acid. That distinction does not create current patent exclusivity because both the ester and acid were expressly claimed and the patent term has ended.

What generic launch risks remain?

Patent 5,089,509 creates no current generic launch risk. The relevant residual risks are commercial and regulatory:

A generic may need to match the reference listed drug’s dosage form and strength.
Topical bioequivalence may require product-specific FDA studies or comparative characterization.
Formulation patents may apply to a specific branded dosage form.
A generic label may need to omit a protected indication if a later method patent remains valid.
Manufacturing processes may be protected separately.
Supply, scale-up and dermatologic tolerability can affect launch timing even without an active compound patent.

For a standard tazarotene generic, the main barriers are likely to be FDA product development, formulation equivalence, manufacturing validation and market economics rather than Patent No. 5,089,509.

What is the geographic coverage of the patent family?

U.S. Patent No. 5,089,509 provides rights only in the United States. Foreign counterparts, if filed, would have had separate prosecution histories, claim scopes and expiration dates. Foreign patent rights cannot be inferred solely from the U.S. patent number or U.S. claims.

The international landscape should therefore be analyzed jurisdiction by jurisdiction, particularly in:

European countries covered by an EP filing.
Canada.
Japan.
Australia.
Major emerging pharmaceutical markets.

A U.S. expiration does not establish that every corresponding foreign patent expired on the same date.

Key Takeaways

U.S. Patent No. 5,089,509 covers tazarotene, tazarotenic acid and related chroman/thiochroman pyridyl-ethynyl compounds.
Claim 4 directly covers tazarotene.
Claim 5 covers tazarotenic acid and its salts.
Claims 18 and 19 cover pharmaceutical compositions and psoriasis treatment methods.
The patent issued January 21, 1992, and expired January 21, 2009.
The patent has no current U.S. blocking effect.
Tazarotene is a small molecule, so biosimilar regulation is not applicable.
Current generic risk depends on FDA requirements and any later formulation, delivery, method-of-use or manufacturing patents.
The patent’s historical value was high because it included direct compound claims.
Foreign rights require separate patent-family and national-phase review.

FAQs

Is tazarotene still patented in the United States?

The compound claims in U.S. Patent No. 5,089,509 expired on January 21, 2009. Any current patent issue would have to arise from a later formulation, delivery, manufacturing or method-of-use patent.

Does Patent 5,089,509 cover tazarotenic acid?

Yes. Claim 5 expressly covers 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid and its pharmaceutically acceptable salts.

Can a generic use the same tazarotene molecule?

Yes, subject to FDA approval requirements and any separately enforceable patents covering the proposed dosage form, formulation, manufacturing process or labeling.

Is tazarotene a biologic subject to biosimilar competition?

No. Tazarotene is a chemically synthesized small molecule regulated through the generic drug pathway rather than the biosimilar pathway.

Does the patent cover tazarotene foam?

The issued claims are not expressly limited to foam. A foam product could have been covered by the broad composition or method claims during the patent term, but current foam-specific risk depends on later formulation and delivery patents.

References

U.S. Patent No. 5,089,509. (1992). United States Patent and Trademark Office.
United States Code, 35 U.S.C. §§ 154, 156. (2024).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application process under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0284288	⤷ Start Trial	SPC/GB98/002	United Kingdom	⤷ Start Trial
European Patent Office	0284288	⤷ Start Trial	12/1998	Austria	⤷ Start Trial
Austria	200284	⤷ Start Trial
Austria	76641	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,089,509

Summary for Patent: 5,089,509